Literature DB >> 29414302

Imaging of human epidermal growth factor receptors for patient selection and response monitoring - From PET imaging and beyond.

Patricia M R Pereira1, Lolkje Abma1, Kelly E Henry1, Jason S Lewis2.   

Abstract

The Human Epidermal Growth Factor Receptor (ErbB/HER) family - EGFR/HER1, ErbB-2/HER2, ErbB-3/HER3, and ErbB-4/HER4 - play a key role in tumor development. Moreover, positive status of HER2 and specific mutations of EGFR are necessary to initiate HER2 directed and EGFR mutation directed therapies. The status of these receptors is usually determined by assaying biopsy specimens of tumor tissues; however, tissue samples are insufficient to account for the complex dynamics and heterogeneity involved in HER status. Molecular imaging of receptors of the HER family have undergone much development, and some show promise for facilitating patient selection for HER therapy and monitoring of treatment response. This review provides a general overview of HER family expression and signaling in tumor tissue and more importantly discusses the available EGFR, HER2 and HER3 molecular imaging modalities, highlighting their use not only for selecting patients for receptor-targeted therapy, but also for monitoring therapeutic response. Additionally, the design and the biological evaluation of HER-specific imaging probes using different cancer models and clinical data are discussed.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer diagnosis; Cancer therapy; HER dynamics; HER heterogeneity; Molecular imaging

Mesh:

Substances:

Year:  2018        PMID: 29414302     DOI: 10.1016/j.canlet.2018.01.052

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  14 in total

1.  Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging.

Authors:  Longguang Tang; Chenyu Peng; Bowen Tang; Zijing Li; Xiangyu Wang; Jindian Li; Fei Gao; Lumei Huang; Duo Xu; Pu Zhang; Rongqiang Zhuang; Xinhui Su; Xiaoyuan Chen; Xianzhong Zhang
Journal:  J Nucl Med       Date:  2018-04-13       Impact factor: 10.057

Review 2.  PET Imaging of Receptor Tyrosine Kinases in Cancer.

Authors:  Weijun Wei; Dalong Ni; Emily B Ehlerding; Quan-Yong Luo; Weibo Cai
Journal:  Mol Cancer Ther       Date:  2018-08       Impact factor: 6.261

3.  Development and characterization of CD54-targeted immunoPET imaging in solid tumors.

Authors:  Weijun Wei; Dawei Jiang; Hye Jin Lee; Miao Li; Christopher J Kutyreff; Jonathan W Engle; Jianjun Liu; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-11       Impact factor: 9.236

4.  EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors.

Authors:  Tran T Hoang; Komal Mandleywala; Tara Viray; Kel Vin Tan; Jason S Lewis; Patricia M R Pereira
Journal:  Mol Imaging Biol       Date:  2022-02-11       Impact factor: 3.484

Review 5.  Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond.

Authors:  Javad Garousi; Anna Orlova; Fredrik Y Frejd; Vladimir Tolmachev
Journal:  EJNMMI Radiopharm Chem       Date:  2020-06-23

6.  Site-specific conjugation allows modulation of click reaction stoichiometry for pretargeted SPECT imaging.

Authors:  Danielle Mandikian; Hanine Rafidi; Pragya Adhikari; Priya Venkatraman; Lidia Nazarova; Gabriel Fung; Isabel Figueroa; Gregory Z Ferl; Sheila Ulufatu; Jason Ho; Cynthia McCaughey; Jeffrey Lau; Shang-Fan Yu; Saileta Prabhu; Jack Sadowsky; C Andrew Boswell
Journal:  MAbs       Date:  2018-10-04       Impact factor: 5.857

7.  Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy.

Authors:  Patrícia M R Pereira; Sai Kiran Sharma; Lukas M Carter; Kimberly J Edwards; Jacob Pourat; Ashwin Ragupathi; Yelena Y Janjigian; Jeremy C Durack; Jason S Lewis
Journal:  Nat Commun       Date:  2018-12-03       Impact factor: 14.919

8.  Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor.

Authors:  Stacey E Rudd; Jessica K Van Zuylekom; Anna Raicevic; Lesley A Pearce; Carleen Cullinane; Charlotte C Williams; Timothy E Adams; Rodney J Hicks; Paul S Donnelly
Journal:  Chem Sci       Date:  2021-05-25       Impact factor: 9.825

9.  Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent - N-succinimidyl 3-(1-(2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate.

Authors:  Zhengyuan Zhou; Darryl McDougald; Rebecca Meshaw; Irina Balyasnikova; Michael R Zalutsky; Ganesan Vaidyanathan
Journal:  Nucl Med Biol       Date:  2021-06-11       Impact factor: 2.947

Review 10.  Antibody Fragment and Affibody ImmunoPET Imaging Agents: Radiolabelling Strategies and Applications.

Authors:  Ruisi Fu; Laurence Carroll; Gokhan Yahioglu; Eric O Aboagye; Philip W Miller
Journal:  ChemMedChem       Date:  2018-11-15       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.